KYMR · Categories · Coverage
KYMR - Analyst coverage initiated
Kymera Therapeutics Inc. (KYMR) analyst coverage initiated - real-time wire coverage filtered to Coverage only.
Recent Coverage for KYMR
- Canaccord Genuity initiated coverage on Kymera Therapeutics with a new price targetCanaccord Genuity initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $106.00
- Mizuho initiated coverage on Kymera Therapeutics with a new price targetMizuho initiated coverage of Kymera Therapeutics with a rating of Outperform and set a new price target of $81.00
- Barclays initiated coverage on Kymera Therapeutics with a new price targetBarclays initiated coverage of Kymera Therapeutics with a rating of Overweight and set a new price target of $60.00
- RBC Capital Mkts initiated coverage on Kymera Therapeutics with a new price targetRBC Capital Mkts initiated coverage of Kymera Therapeutics with a rating of Outperform and set a new price target of $70.00
- Citigroup initiated coverage on Kymera Therapeutics with a new price targetCitigroup initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $52.00
- BTIG Research initiated coverage on Kymera Therapeutics with a new price targetBTIG Research initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $60.00
- BMO Capital Markets initiated coverage on Kymera Therapeutics with a new price targetBMO Capital Markets initiated coverage of Kymera Therapeutics with a rating of Market Perform and set a new price target of $55.00
- Stephens initiated coverage on Kymera Therapeutics with a new price targetStephens initiated coverage of Kymera Therapeutics with a rating of Overweight and set a new price target of $65.00
- Oppenheimer initiated coverage on Kymera Therapeutics with a new price targetOppenheimer initiated coverage of Kymera Therapeutics with a rating of Outperform and set a new price target of $53.00
- Wolfe Research initiated coverage on Kymera TherapeuticsWolfe Research initiated coverage of Kymera Therapeutics with a rating of Peer Perform
- Truist initiated coverage on Kymera Therapeutics with a new price targetTruist initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $50.00
- Raymond James initiated coverage on Kymera TherapeuticsRaymond James initiated coverage of Kymera Therapeutics with a rating of Mkt Perform
- Jefferies initiated coverage on Kymera Therapeutics with a new price targetJefferies initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $40.00
- Goldman initiated coverage on Kymera Therapeutics with a new price targetGoldman initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $40.00
- SVB Leerink initiated coverage on Kymera Therapeutics with a new price targetSVB Leerink initiated coverage of Kymera Therapeutics with a rating of Mkt Perform and set a new price target of $26.00
- Credit Suisse initiated coverage on Kymera Therapeutics with a new price targetCredit Suisse initiated coverage of Kymera Therapeutics with a rating of Outperform and set a new price target of $63.00
- JP Morgan initiated coverage on Kymera Therapeutics with a new price targetJP Morgan initiated coverage of Kymera Therapeutics with a rating of Neutral and set a new price target of $44.00
- Wells Fargo initiated coverage on Kymera Therapeutics with a new price targetWells Fargo initiated coverage of Kymera Therapeutics with a rating of Overweight and set a new price target of $62.00
- B. Riley Securities initiated coverage on Kymera Therapeutics with a new price targetB. Riley Securities initiated coverage of Kymera Therapeutics with a rating of Neutral and set a new price target of $67.00
- Stifel initiated coverage on Kymera Therapeutics with a new price targetStifel initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $80.00
- UBS initiated coverage on Kymera Therapeutics with a new price targetUBS initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $80.00
- Berenberg initiated coverage on Kymera TherapeuticsBerenberg initiated coverage of Kymera Therapeutics with a rating of Buy